ADAM8 as a drug target in pancreatic cancer

Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Hofling S, Parsons M, Costa P, Soper R, Bossard M, et al. (2015)

Zeitschriftenaufsatz | Veröffentlicht | Englisch
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Schlomann, Uwe; Koller, Garrit; Conrad, Catharina; Ferdous, Taheera; Golfi, Panagiota; Garcia, Adolfo Molejon; Hofling, Sabrina; Parsons, Maddy; Costa, Patricia; Soper, Robin; Bossard, Maud; Hagemann, Thorsten
Abstract / Bemerkung
Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with <5% survivors after 5 years. High expression levels of ADAM8, a metalloprotease disintegrin, are correlated with poor clinical outcome. We show that ADAM8 expression is associated with increased migration and invasiveness of PDAC cells caused by activation of ERK1/2 and higher MMP activities. For biological function, ADAM8 requires multimerization and associates with beta 1 integrin on the cell surface. A peptidomimetic ADAM8 inhibitor, BK-1361, designed by structural modelling of the disintegrin domain, prevents ADAM8 multimerization. In PDAC cells, BK-1361 affects ADAM8 function leading to reduced invasiveness, and less ERK1/2 and MMP activation. BK-1361 application in mice decreased tumour burden and metastasis of implanted pancreatic tumour cells and provides improved metrics of clinical symptoms and survival in a Kras(G12D)-driven mouse model of PDAC. Thus, our data integrate ADAM8 in pancreatic cancer signalling and validate ADAM8 as a target for PDAC therapy.
Page URI


Schlomann U, Koller G, Conrad C, et al. ADAM8 as a drug target in pancreatic cancer. NATURE COMMUNICATIONS. 2015;6(1): 6175.
Schlomann, U., Koller, G., Conrad, C., Ferdous, T., Golfi, P., Garcia, A. M., Hofling, S., et al. (2015). ADAM8 as a drug target in pancreatic cancer. NATURE COMMUNICATIONS, 6(1), 6175. doi:10.1038/ncomms7175
Schlomann, Uwe, Koller, Garrit, Conrad, Catharina, Ferdous, Taheera, Golfi, Panagiota, Garcia, Adolfo Molejon, Hofling, Sabrina, et al. 2015. “ADAM8 as a drug target in pancreatic cancer”. NATURE COMMUNICATIONS 6 (1): 6175.
Schlomann, U., Koller, G., Conrad, C., Ferdous, T., Golfi, P., Garcia, A. M., Hofling, S., Parsons, M., Costa, P., Soper, R., et al. (2015). ADAM8 as a drug target in pancreatic cancer. NATURE COMMUNICATIONS 6:6175.
Schlomann, U., et al., 2015. ADAM8 as a drug target in pancreatic cancer. NATURE COMMUNICATIONS, 6(1): 6175.
U. Schlomann, et al., “ADAM8 as a drug target in pancreatic cancer”, NATURE COMMUNICATIONS, vol. 6, 2015, : 6175.
Schlomann, U., Koller, G., Conrad, C., Ferdous, T., Golfi, P., Garcia, A.M., Hofling, S., Parsons, M., Costa, P., Soper, R., Bossard, M., Hagemann, T., Roshani, R., Sewald, N., Ketchem, R.R., Moss, M.L., Rasmussen, F.H., Miller, M.A., Lauffenburger, D.A., Tuveson, D.A., Nimsky, C., Bartsch, J.W.: ADAM8 as a drug target in pancreatic cancer. NATURE COMMUNICATIONS. 6, : 6175 (2015).
Schlomann, Uwe, Koller, Garrit, Conrad, Catharina, Ferdous, Taheera, Golfi, Panagiota, Garcia, Adolfo Molejon, Hofling, Sabrina, Parsons, Maddy, Costa, Patricia, Soper, Robin, Bossard, Maud, Hagemann, Thorsten, Roshani, Rozita, Sewald, Norbert, Ketchem, Randal R., Moss, Marcia L., Rasmussen, Fred H., Miller, Miles A., Lauffenburger, Douglas A., Tuveson, David A., Nimsky, Christopher, and Bartsch, Jorg W. “ADAM8 as a drug target in pancreatic cancer”. NATURE COMMUNICATIONS 6.1 (2015): 6175.

22 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.
Miyauchi M, Koya J, Arai S, Yamazaki S, Honda A, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M., Stem Cell Reports 10(3), 2018
PMID: 29429960
Fine Tuning Cell Migration by a Disintegrin and Metalloproteinases.
Dreymueller D, Theodorou K, Donners M, Ludwig A., Mediators Inflamm 2017(), 2017
PMID: 28260841
The metalloproteinase ADAM8 promotes leukocyte recruitment in vitro and in acute lung inflammation.
Dreymueller D, Pruessmeyer J, Schumacher J, Fellendorf S, Hess FM, Seifert A, Babendreyer A, Bartsch JW, Ludwig A., Am J Physiol Lung Cell Mol Physiol 313(3), 2017
PMID: 28596294
Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions.
Olivares O, Mayers JR, Gouirand V, Torrence ME, Gicquel T, Borge L, Lac S, Roques J, Lavaut MN, Berthezène P, Rubis M, Secq V, Garcia S, Moutardier V, Lombardo D, Iovanna JL, Tomasini R, Guillaumond F, Vander Heiden MG, Vasseur S., Nat Commun 8(), 2017
PMID: 28685754
Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases.
Amar S, Minond D, Fields GB., Proteomics 17(23-24), 2017
PMID: 28613012
YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells.
Chen J, Sun Y, Xu X, Wang D, He J, Zhou H, Lu Y, Zeng J, Du F, Gong A, Xu M., Cell Cycle 16(23), 2017
PMID: 29135329
Excretion/secretion products from Schistosoma mansoni adults, eggs and schistosomula have unique peptidase specificity profiles.
Dvořák J, Fajtová P, Ulrychová L, Leontovyč A, Rojo-Arreola L, Suzuki BM, Horn M, Mareš M, Craik CS, Caffrey CR, O'Donoghue AJ., Biochimie 122(), 2016
PMID: 26409899
ADAM Proteases and Gastrointestinal Function.
Jones JC, Rustagi S, Dempsey PJ., Annu Rev Physiol 78(), 2016
PMID: 26667078
The ADAMs family of proteases as targets for the treatment of cancer.
Mullooly M, McGowan PM, Crown J, Duffy MJ., Cancer Biol Ther 17(8), 2016
PMID: 27115328
A novel peptide ADAM8 inhibitor attenuates bronchial hyperresponsiveness and Th2 cytokine mediated inflammation of murine asthmatic models.
Chen J, Deng L, Dreymüller D, Jiang X, Long J, Duan Y, Wang Y, Luo M, Lin F, Mao L, Müller B, Koller G, Bartsch JW., Sci Rep 6(), 2016
PMID: 27458083
Shedding of Endogenous Interleukin-6 Receptor (IL-6R) Is Governed by A Disintegrin and Metalloproteinase (ADAM) Proteases while a Full-length IL-6R Isoform Localizes to Circulating Microvesicles.
Schumacher N, Meyer D, Mauermann A, von der Heyde J, Wolf J, Schwarz J, Knittler K, Murphy G, Michalek M, Garbers C, Bartsch JW, Guo S, Schacher B, Eickholz P, Chalaris A, Rose-John S, Rabe B., J Biol Chem 290(43), 2015
PMID: 26359498
The concept and controversy of retroperitoneal nerve dissection in pancreatic head carcinoma (Review).
Wang X, Zhang H, Wang T, Lau WY, Wang X, Sun J, Yuan Z, Zhang Y., Int J Oncol 47(6), 2015
PMID: 26458369
β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer.
Blandin AF, Renner G, Lehmann M, Lelong-Rebel I, Martin S, Dontenwill M., Front Pharmacol 6(), 2015
PMID: 26635609

60 References

Daten bereitgestellt von Europe PubMed Central.

Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans.
Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M, Nikolov DB., Cell 123(2), 2005
PMID: 16239146
The ADAMs: signalling scissors in the tumour microenvironment.
Murphy G., Nat. Rev. Cancer 8(12), 2008
PMID: 19005493
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis.
Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barille-Nion S, Georgakoudi I, Dagg A, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE., EMBO Mol Med 6(2), 2013
PMID: 24375628
Alpha9beta1: a novel osteoclast integrin that regulates osteoclast formation and function.
Rao H, Lu G, Kajiya H, Garcia-Palacios V, Kurihara N, Anderson J, Patrene K, Sheppard D, Blair HC, Windle JJ, Choi SJ, Roodman GD., J. Bone Miner. Res. 21(10), 2006
PMID: 16995821
Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice.
Grippo PJ, Fitchev PS, Bentrem DJ, Melstrom LG, Dangi-Garimella S, Krantz SB, Heiferman MJ, Chung C, Adrian K, Cornwell ML, Flesche JB, Rao SM, Talamonti MS, Munshi HG, Crawford SE., Gut 61(10), 2012
PMID: 22234980
Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8.
Naus S, Reipschlager S, Wildeboer D, Lichtenthaler SF, Mitterreiter S, Guan Z, Moss ML, Bartsch JW., Biol. Chem. 387(3), 2006
PMID: 16542157
Metalloprotease-disintegrin ADAM8: expression analysis and targeted deletion in mice.
Kelly K, Hutchinson G, Nebenius-Oosthuizen D, Smith AJ, Bartsch JW, Horiuchi K, Rittger A, Manova K, Docherty AJ, Blobel CP., Dev. Dyn. 232(1), 2005
PMID: 15580619
ADAMs: key components in EGFR signalling and development.
Blobel CP., Nat. Rev. Mol. Cell Biol. 6(1), 2005
PMID: 15688065
ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice.
Guaiquil VH, Swendeman S, Zhou W, Guaiquil P, Weskamp G, Bartsch JW, Blobel CP., J. Mol. Med. 88(5), 2010
PMID: 20119708
The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion.
Schlomann U, Wildeboer D, Webster A, Antropova O, Zeuschner D, Knight CG, Docherty AJ, Lambert M, Skelton L, Jockusch H, Bartsch JW., J. Biol. Chem. 277(50), 2002
PMID: 12372841
Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression.
Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG., Biochem. J. 441(2), 2012
PMID: 22187935
BMP2 induces PANC-1 cell invasion by MMP-2 overexpression through ROS and ERK.
Liu J, Ben QW, Yao WY, Zhang JJ, Chen DF, He XY, Li L, Yuan YZ., Front Biosci (Landmark Ed) 17(), 2012
PMID: 22652796
ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis.
Fritzsche FR, Jung M, Xu C, Rabien A, Schicktanz H, Stephan C, Dietel M, Jung K, Kristiansen G., Virchows Arch. 449(6), 2006
PMID: 17106710
ADAMs in cancer cell proliferation and progression.
Mochizuki S, Okada Y., Cancer Sci. 98(5), 2007
PMID: 17355265
Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities.
Miller MA, Barkal L, Jeng K, Herrlich A, Moss M, Griffith LG, Lauffenburger DA., Integr Biol (Camb) 3(4), 2010
PMID: 21180771
Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain.
Lorenzen I, Trad A, Grotzinger J., Biochem. Biophys. Res. Commun. 415(2), 2011
PMID: 22033402
Genetics and biology of pancreatic ductal adenocarcinoma.
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA., Genes Dev. 20(10), 2006
PMID: 16702400
Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion.
Layton T, Stalens C, Gunderson F, Goodison S, Silletti S., Am. J. Pathol. 175(6), 2009
PMID: 19893036
Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding.
Gomez-Gaviro M, Dominguez-Luis M, Canchado J, Calafat J, Janssen H, Lara-Pezzi E, Fourie A, Tugores A, Valenzuela-Fernandez A, Mollinedo F, Sanchez-Madrid F, Diaz-Gonzalez F., J. Immunol. 178(12), 2007
PMID: 17548643
Knockdown of the β(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis.
Grzesiak JJ, Tran Cao HS, Burton DW, Kaushal S, Vargas F, Clopton P, Snyder CS, Deftos LJ, Hoffman RM, Bouvet M., Int. J. Cancer 129(12), 2011
PMID: 21491421
Therapeutic benefits from targeting of ADAM family members.
Moss ML, Bartsch JW., Biochemistry 43(23), 2004
PMID: 15182168
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.
Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA., Cancer Cell 4(6), 2003
PMID: 14706336
Integrin alpha4beta1-dependent adhesion to ADAM 28 (MDC-L) requires an extended surface of the disintegrin domain.
Bridges LC, Hanson KR, Tani PH, Mather T, Bowditch RD., Biochemistry 42(13), 2003
PMID: 12667064
Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer.
Hernandez I, Moreno JL, Zandueta C, Montuenga L, Lecanda F., Oncogene 29(26), 2010
PMID: 20453887
Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma.
Li Z, Liao Q, Wu Y, Liao M, Hao Y, Zhang S, Song S, Li B, Zhang YD., Pathol. Oncol. Res. 18(3), 2012
PMID: 22215309
ADAM8 as a novel serological and histochemical marker for lung cancer.
Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y., Clin. Cancer Res. 10(24), 2004
PMID: 15623614
Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta 1: implications for sperm-egg binding and other cell interactions.
Eto K, Huet C, Tarui T, Kupriyanov S, Liu HZ, Puzon-McLaughlin W, Zhang XP, Sheppard D, Engvall E, Takada Y., J. Biol. Chem. 277(20), 2002
PMID: 11882657
Tumorigenesis: Pushing pancreatic cancer to take off.
Seton-Rogers S., Nat. Rev. Cancer 12(11), 2012
PMID: 23037449
EMT and dissemination precede pancreatic tumor formation.
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ., Cell 148(1-2), 2012
PMID: 22265420
ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer.
Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, Friess H, Kleeff J., J. Cell. Mol. Med. 11(5), 2007
PMID: 17979891
ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271).
Zack MD, Malfait AM, Skepner AP, Yates MP, Griggs DW, Hall T, Hills RL, Alston JT, Nemirovskiy OV, Radabaugh MR, Leone JW, Arner EC, Tortorella MD., Arthritis Rheum. 60(9), 2009
PMID: 19714641
Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3.
Zhang XP, Kamata T, Yokoyama K, Puzon-McLaughlin W, Takada Y., J. Biol. Chem. 273(13), 1998
PMID: 9516430
ADAM8/MS2/CD156, an emerging drug target in the treatment of inflammatory and invasive pathologies.
Koller G, Schlomann U, Golfi P, Ferdous T, Naus S, Bartsch JW., Curr. Pharm. Des. 15(20), 2009
PMID: 19601829
Molecular cloning of cDNA encoding MS2 antigen, a novel cell surface antigen strongly expressed in murine monocytic lineage.
Yoshida S, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S., Int. Immunol. 2(6), 1990
PMID: 1982220
Cell-surface metalloprotease ADAM12 is internalized by a clathrin- and Grb2-dependent mechanism.
Stautz D, Leyme A, Grandal MV, Albrechtsen R, van Deurs B, Wewer U, Kveiborg M., Traffic 13(11), 2012
PMID: 22882974
Quantification of integrin receptor agonism by fluorescence lifetime imaging.
Parsons M, Messent AJ, Humphries JD, Deakin NO, Humphries MJ., J. Cell. Sci. 121(Pt 3), 2008
PMID: 18216331
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies.
Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F., Cell 148(1-2), 2012
PMID: 22265421
ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study.
Zielinski V, Brunner M, Heiduschka G, Schneider S, Seemann R, Erovic B, Thurnher D., BMC Cancer 12(), 2012
PMID: 22369429
EGF receptor is required for KRAS-induced pancreatic tumorigenesis.
Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT., Cancer Cell 22(3), 2012
PMID: 22975374
Role of ADAM-9 disintegrin-cysteine-rich domains in human keratinocyte migration.
Zigrino P, Steiger J, Fox JW, Loffek S, Schild A, Nischt R, Mauch C., J. Biol. Chem. 282(42), 2007
PMID: 17704059
CD156 (human ADAM8): expression, primary amino acid sequence, and gene location.
Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S., Genomics 41(1), 1997
PMID: 9126482
Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1.
Botta GP, Reginato MJ, Reichert M, Rustgi AK, Lelkes PI., Mol. Cancer Res. 10(2), 2011
PMID: 22160930
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.
Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M., Cancer Cell 22(3), 2012
PMID: 22975375
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.
Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H., Nat Rev Gastroenterol Hepatol 9(8), 2012
PMID: 22710569
Dual function of focal adhesion kinase in regulating integrin-induced MMP-2 and MMP-9 release by human T lymphoid cells.
Segarra M, Vilardell C, Matsumoto K, Esparza J, Lozano E, Serra-Pages C, Urbano-Marquez A, Yamada KM, Cid MC., FASEB J. 19(13), 2005
PMID: 16260653

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

PMID: 25629724
PubMed | Europe PMC

Suchen in

Google Scholar